Effektivnost' i bezopasnost' ezhenedel'nogo vvedeniya paklitaksela bol'nym metastaticheskim rakom molochnoy zhelezy: rezul'taty prospektivnogo mnogotsentrovogo klinicheskogo issledovaniya
- Autores: Stroyakovskiy D.L.1, Makhson A.N.1, Bolotina L.V.1, Gorbunova V.A.1, Koroleva L.A.1, Bagrova S.G.1, Borisova T.A.1, Kornietskaya A.L.1, Ivanov R.A.1, Nikitin K.D.1
-
Afiliações:
- Edição: Nº 8 (2012)
- Páginas: 68-73
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279566
- ID: 279566
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Daniil Stroyakovskiy
Anatoliy Makhson
Larisa Bolotina
Vera Gorbunova
Lyudmila Koroleva
Svetlana Bagrova
Tat'yana Borisova
Anna Kornietskaya
Roman Ivanov
Kirill Nikitin
Bibliografia
- Злокачественные новообразования в России в 2010 году (заболеваемость и смертность) / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012. 260 с. ил.
- Abrams JS, Vena DA, Batz J, et al. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13: 2056-65.
- Cardoso F, Bedard PL, Winer EP, et al.; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101(17):1174-81.
- Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(5):15-9.
- Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
- Pentheroudakis G, Razis E, Athanassiadis A, et al. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006;23(2):147-60.
- Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;6(5):425-32.
- Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
- Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
- Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 2-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403-11.
- ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicenter phase II trial. Eur J Cancer 2004;40:352-57.
- Wist EA, Sommer HH, Ostenstad B, et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004;3:11-4.